A randomized, double-blind, placebo-controlled, dose-ranging, study to evaluate the efficacy, safety and tolerability of single doses of BCX7353 as an acute attack treatment in subjects with hereditary angioedema
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2017
At a glance
- Drugs BCX 7353 (Primary)
- Indications Hereditary angioedema
- Focus Therapeutic Use
- Acronyms ZENITH-1
- Sponsors BioCryst Pharmaceuticals
- 03 Aug 2017 Planned End Date changed from 10 May 2018 to 1 Nov 2018.
- 02 Aug 2017 According to a BioCryst Pharmaceuticals media release, the first subject has been dosed in this trial.
- 22 May 2017 Status changed from planning to recruiting.